Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market, By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (B-cell Lymphoblastic Leukemia/Lymphoma, and T-cell Lymphoblastic Leukemia), Age Group (Below 21, 21-29, 30-65, 65 and Above), Gender (Male and Female) End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales) Industry Trends and Forecast to 2030.
Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market Analysis and Insights
Blood cancer has been the most common cancer worldwide for several decades. The incidence rates of cancer have been on the rise both for males and females. It occurs slightly more frequently in males than females. Acute lymphocytic leukemia (ALL) accounts for approximately two percent of the lymphoid neoplasms in the U.S. Patients typically present with symptoms related to anemia, thrombocytopenia, and neutropenia due to the replacement of the bone marrow with the tumor. The high competition in leukemia diagnostics therapeutics and the need for improved diagnostics worldwide has increased the demand for various services in this sector. Various companies have launched numerous diagnostics products to meet the world's surging demand for the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.
However, the high cost of treatment for leukemia cancer including the therapies, medicines, and others, is one of the most significant factors. As a result, market growth may be hampered in the long run. The cost of diagnostic products is one element that may challenge leukemia diagnosis device vendors.
Data Bridge Market Research analyzes that the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is expected to reach a value of USD 332.05 million by 2030, at a CAGR of 8.1% during the forecast period. Product type accounts for the largest segment in the market due to the rapid demand for leukemia diagnostics in the Asia-Pacific. This market report also covers pricing analysis, patent analysis, and technological advancements in depth.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2020-2016)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (B-cell Lymphoblastic Leukemia/Lymphoma, and T-cell Lymphoblastic Leukemia), Age Group (Below 21, 21-29, 30-65, 65 and Above), Gender (Male and Female) End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales)
|
|
Countries Covered
|
China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and the Rest of Asia-Pacific.
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN, Abbott, Merck KGaA, Siemens Medical Solutions USA, Inc., Hologic, Inc., Agilent Technologies, Inc., DiaSorin S.p.A., Illumina, Inc., Myriad Genetics, Inc., bioMérieux SA, Quest Diagnostics Incorporated, Bio-Rad Laboratories, Inc., Koninklijke Philips N.V., BD, Exact Sciences Corporation, Time Medical Holding, PlexBio, MinFound Medical Systems Co., Ltd, Medonica Co. LTD among others
|
Market Definition
Acute lymphocytic leukemia (ALL) is a malignancy of B or T-lymphoblasts characterized by uncontrolled proliferation of abnormal, immature lymphocytes and their progenitors, which ultimately leads to the replacement of bone marrow elements and other lymphoid organs resulting in a characteristic disease pattern. B-cells are a specific type of lymph cell that affect a body's immune system. Two types of B-cell leukemia are prolymphocytic leukemia (PLL) and Hairy Cell Leukemia (HCL). Symptoms include fatigue, easy or spontaneous bruising and bleeding, and infections. Additionally, B-symptoms, such as fever, night sweats, and unintentional weight loss, are often present but may be mild, and hepatomegaly, splenomegaly, and lymphadenopathy can be seen in up to half of adults on presentation. Central Nervous System (CNS) involvement is common and can be accompanied by cranial neuropathies or symptoms, predominantly meningeal, related to increased intracranial pressure. T-cell lymphoblastic leukemia is most common among children aged over five years. The increasing cases of cancer worldwide and the rising prevalence of lymphoblastic leukemia are expected to drive segmental T-cell acute lymphoblastic leukemia market growth. These white blood cell acutely influences white platelets called T- lymphocytes. The Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is expected to show significant growth due to the rising prevalence of T-cell acute lymphoblastic leukemia, research and development activities, and high healthcare expenditure.
Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Growing prevalence of leukemia cancer
All ages can be affected by leukemia. Leukemia can be difficult to diagnose because, despite its wide range of signs and symptoms, they are non-specific and can be linked to other, more widespread medical conditions. Acute lymphoblastic leukemia has the highest emergency presenting rates of any cancer kind, with a leukemia emergency diagnostic rate of 37% on average.
The most frequent form of juvenile cancer is acute lymphoblastic leukemia, a heterogeneous illness defined by unchecked lymphoid progenitor proliferation that typically begins in utero. Although the prevalence of ALL has been rising significantly in recent decades, there is still no apparent cause for this development. Rising maternal obesity rates may be partially responsible for the rise in ALL prevalence.
Thus, acute leukemia incidence has been rising Asia-Pacificly due to various risk factors, becoming a significant socio-economic issue. This is expected to act as a driver in the Asia-Pacific acute lymphocytic\lymphoblastic leukemia (ALL) diagnostics market.
- Novel technological advancements in leukemia diagnostics
The most common form of blood cancer, acute lymphoblastic leukemia (ALL), is also one of the main causes of death. The blood is invaded by this form of cancer, which then spreads to nearby organs and bodily systems. Specialists must manually diagnose cancer and non-cancer cells by examining cell images under a microscope and providing labels through annotation. However, this hand microscopic examination is time-consuming and could give an incorrect diagnosis.
The risk of prescribing the incorrect drugs was then reduced using computerized software. The creation of an automatic and reliable classification system became vital to stop the leukemia disease's devastating effects. Multiple segmentation techniques constituted the foundation of the existing leukemia classification algorithms.
The manual examination of stained blood smear microscopy pictures used in current practice for the initial diagnosis of ALL is time-consuming and prone to error. A potent tool for aiding doctors in making medical decisions has emerged: deep learning-based human-centric biomedical diagnostics. Various computer-aided diagnostic techniques have been created to recognize ALL blood pictures automatically.
The development of several new diagnostic methods will increase the market's growth as many new and advanced products are launched. Hence, it is expected to create demand for acute leukemic cancer diagnosis in the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.
Restraint
- Late diagnosis and poor prognosis of leukemia
Cancer is the leading cause of death Asia-Pacificly. By 2030, it is anticipated that there will be 13.1 million more cancer-related deaths per year. However, if they are identified early on and given the right care, some cancers can be cured. The diagnostic process may experience delays in cancer diagnosis. When patients overlook or fail to respond to potentially cancerous signs, patient delays may result. The main cause of delayed presentation is thought to be a lack of public knowledge of early cancer signs, especially if such symptoms are unusual.
The late diagnosis often results from these factors, which result in poor prognosis. Thus, these are expected to restrain the growth of the Asia-Pacific acute lymphocytic\lymphoblastic leukemia (ALL) diagnostics market.
Opportunities
- Increase in diagnostic products for leukemia
A blood-forming tissue cancer impairs the body's capability to combat infection. Bone marrow is one of the blood-forming tissues that can develop leukemia. Numerous varieties include chronic lymphocytic leukemia, acute myeloid leukemia, and acute lymphoblastic leukemia. Many patients with leukemia that grow slowly do not exhibit any symptoms. Fatigue, weight loss, recurrent infections, and easy bruising or bleeding are all possible symptoms of leukemia that grow quickly. Treatment results vary greatly. Treatment for leukemia with a slow growth rate may involve monitoring. Chemotherapy for malignant leukemia is occasionally combined with radiation therapy and stem cell transplant.
Thus, the rise in diagnostic product approvals has led to an increased number of highly efficient products in the market for leukemia diagnosis treatment. This is expected to create an opportunity for the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.
- Government initiatives toward cancer diagnostics
The government plays a major role while taking the initiative for cancer diseases because cancer is a leading disease worldwide. Leukemia has increased very rapidly in individuals in past decades. Leukemia is the most prevalent cancer, with 60,650 new cases in 2022, according to cancer.gov.
There are several initiatives taken by the government that helps boost the market's demand, and these initiatives will increase awareness among people regarding their health and take early diagnosis for better cure and precaution. For this reason, government initiatives towards cancer diagnostics are acting as an opportunity for growing the demand of the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.
Challenge
- Increased cost, safety, and convenience issue
Leukemia is fatal cancer, and the diagnosis process of leukemia also has safety issues; it is not cost-effective. One of the most costly medical disorders to treat Asia-Pacificly is cancer. Cancer patients may be hospitalized and receive a variety of therapies, such as surgery, radiation therapy, and systemic therapy. Health insurance premiums for cancer patients are now more expensive than in the past. In addition, their copayment, deductible, and coinsurance costs are rising.
Rising helium shortage and rising risk of excessive radiation exposure are projected to restrict the use of CT scanners, threatening the possibilities of rising capital investments and low benefit-cost ratio for biomarkers. Many hospitals in developing countries cannot invest in diagnostic imaging equipment, which has led to an increase in the use of reconstructed diagnostic imaging due to high expenditures and financial restrictions. Due to the increasing demand for diagnostic imaging operations in these nations, hospitals that can't afford to buy new, cutting-edge imaging systems instead choose to employ refurbished imaging equipment, which could have long-term negative effects.
Henceforth, the current leukemia diagnosis process has safety, cost, and convenience issues, which are expected to challenge the growth of the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.
Post-COVID-19 Impact on Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market
The cancer diagnostics market has been badly affected by COVID-19. Hospital admissions were limited to non-essential treatment, and clinics were temporarily closed during the pandemic. The implementation of social distancing, blocking the population, and limited access to clinics have greatly affected the market. The slowdown in patient flows and referrals also affected the market growth. However, the market will continue to grow in the post-pandemic period due to the relaxation of previously imposed restrictions.
Manufacturers make various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results in the cancer diagnostics market.
Recent Developments
- In October 2022, Thermo Fisher Scientific Inc. announced that it had entered into a definitive agreement to acquire The Binding Site Group, a Asia-Pacific leader in specialty diagnostics. The acquisition will help in the development of the specialty diagnostics segment.
- In August 2022, F. Hoffmann-La Roche Ltd. announced the launch of a Digital LightCycler System. This next-generation digital PCR system helps clinical researchers better understand the nature of a patient's cancer, genetic disease, or infection. This system is designed for laboratories performing highly sensitive and precise DNA and RNA analysis in oncology and infectious diseases.
Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market Scope
The Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into product type, test type, cancer type, age group, gender, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Product Type
- Instruments
- Consumables & Accessories
On the basis of product type, the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into instruments, consumables & accessories.
Test Type
- Imaging Test
- Biopsy
- Blood Test
- Others
On the basis of test type, the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into imaging test, biopsy, blood test, and others.
Cancer Type
- B-cell Lymphoblastic Leukemia /Lymphoma
- T-cell Lymphoblastic Leukemia
On the basis of cancer type, the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into B-cell lymphoblastic leukemia/lymphoma and T-cell lymphoblastic leukemia.
By Age Group
- Below 21
- 21-29
- 30-65
- 65 and Above
On the basis of age group, the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into below 21, 21-29, 30-65, 65 and above.
By Gender
- Male
- Female
On the basis of gender, the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into male and female.
By End User
- Hospital
- Associated Labs
- Independent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
- Others
On the basis of end user, the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into hospital, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.
By Distribution Channel
- Direct Tender
- Retail Sales
On the basis of distribution channel, the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into direct tender and retail sales.
Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market Regional Analysis/Insights
The Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is analyzed, and market size information is provided by country, product type, test type, cancer type, age group, gender, end user, and distribution channel.
Some countries covered in this Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market are China, Japan, India, South Korea, Singapore, Vietnam, Thailand, Malaysia, Australia, the Philippines, Indonesia, and the rest of the Asia-Pacific.
China is expected to grow due to novel technological advancements in leukemia diagnostics in the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.
The country section of the report also provides individual market-impacting factors and domestic regulation changes that impact the market's current and future trends. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market Share Analysis
The Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the company's focus on the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.
Some of the major players operating in the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN, Abbott, Merck KGaA, Siemens Medical Solutions USA, Inc., Hologic, Inc., Agilent Technologies, Inc., DiaSorin S.p.A., Illumina, Inc., Myriad Genetics, Inc., bioMérieux SA, Quest Diagnostics Incorporated, Bio-Rad Laboratories, Inc., Koninklijke Philips N.V., BD, Exact Sciences Corporation, Time Medical Holding, PlexBio, MinFound Medical Systems Co., Ltd, Medonica Co. LTD among others.
SKU-